Chemotherapeutic Toxicity Clinical Trial
Official title:
Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy. - an Open , Multicenter, Non-interventional Clinical Trial
This is an open , multicenter, interventional clinical trial to conform the role of of miR-122 a real-time detection biomarker of drug-induced liver injury by chemotherapy.
The endorsed standard serum biomarkers, like ALT, AST, total bilirubin, are not tissue-specific, and cannot detect drug-induced liver injury (DILI) at a very early stage, thus unable to properly guide risk assessment and patient management. miR-122 is a liver-enriched miRNA. Many studies have demonstrated that miR-122 is a sensitive and specific biomarker when DILI occurred. However, there is a lack of a standard quantification method for miR-122 and confirmatory studies using a comprehensive list of drugs and patients. The investigators have developed the miRNA-derived Fragment Length Polymorphism (miRFLP) assay for the simultaneous quantification of multiple miRNAs.The methodology improves detection reliability by eliminating intra-assay variables. In this study, the investigators will investigate the role of miR-122 as a real-time detection biomarker of drug-induced liver injury utilizing the miRFLP assay. In addition, the investigators will try to identify the normal physiological range of miR-122 in healthy population and the relationship of miR-122 and hepatic failure in patients of intensive care unit. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04277650 -
System for High-Intensity Evaluation During Radiotherapy
|
N/A | |
| Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
| Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
| Recruiting |
NCT06197581 -
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
|
N/A | |
| Not yet recruiting |
NCT04965532 -
Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia
|
N/A | |
| Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
| Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
| Terminated |
NCT04607668 -
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
|
Phase 3 | |
| Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A | |
| Recruiting |
NCT06357871 -
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
|
||
| Completed |
NCT02996201 -
Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
|
N/A | |
| Completed |
NCT00292526 -
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
|
Phase 4 | |
| Completed |
NCT04663178 -
Foot Bath and Chemotherapy Induced Fatigue
|
N/A | |
| Recruiting |
NCT03191461 -
Myocardial Perfusion and Fibrosis in Cancer Survivors
|
||
| Recruiting |
NCT05251922 -
Tolerance of Anti-Cancer Therapy in the Elderly
|
||
| Recruiting |
NCT05892146 -
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
|
N/A | |
| Recruiting |
NCT05302336 -
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
|
Phase 4 | |
| Completed |
NCT05512676 -
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
|
||
| Completed |
NCT04799080 -
Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function
|
||
| Completed |
NCT04694794 -
Diminish Chemotherapy Related Side Effects Through Patient Education
|
N/A |